The argument of the ORBITA study: angioplasty is useless

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Stable coronary artery disease (CAD) treatment aims to improve patient prognosis and quality of life.
• Revascularization procedures like coronary angioplasty are guideline-supported for symptomatic patients refractory to optimal medical treatment.
• Previous research indicated angioplasty effectively reduces angina and enhances functional capacity in CAD patients.

Purpose of the Study:

• To evaluate the efficacy of coronary angioplasty versus a sham procedure in patients with stable single-vessel coronary artery disease.
• To assess the impact of angioplasty on objective measures of exercise tolerance and patient-reported symptoms.

Main Methods:

• The ORBITA study was a randomized, double-blind, placebo-controlled trial.
• Participants with stable CAD and angina underwent invasive physiological assessment, followed by either angioplasty or a sham procedure.
• Primary endpoint was improvement in exercise tolerance.

Main Results:

• Coronary angioplasty did not demonstrate a significant benefit over the placebo procedure in improving exercise tolerance.
• No significant differences were observed in angina frequency or quality of life between the groups.
• These findings challenge the routine use of angioplasty for symptom relief in this patient population.

Conclusions:

• The ORBITA study suggests that in selected patients with stable single-vessel CAD, the procedural benefit of angioplasty may be limited.
• Further research is needed to define the role of revascularization in stable CAD, considering both symptom relief and prognostic benefits.
• Optimal medical therapy remains a cornerstone in managing stable coronary artery disease.